Pinealon is the most talked-about brain peptide in the Khavinson family after Epithalon. It is the tripeptide Glu-Asp-Arg (EDR), sold as Cytogen capsules “for brain function” and as injectable vials. The name suggests the pineal gland, but the research and the marketing are about neurons, oxidative stress and cognition.
My verdict: Pinealon has more cell and mouse data than most bioregulators, and one small Russian human study that reported benefits but did not describe a control group. Better than nothing, still far from proof.
The class is explained in the peptide bioregulators overview.
At a Glance
| Property | Detail |
|---|---|
| Sequence | Glu-Asp-Arg (EDR), synthetic tripeptide |
| Origin | Khavinson group, St. Petersburg; Cytogen product line |
| Proposed mechanism | Limits reactive oxygen species and necrotic cell death in neurons; DNA binding and gene regulation (cell and modelling data) |
| Marketed for | Cognitive aging, brain fog, stress resilience, neuroprotection |
| Route | Oral capsules (Cytogen); SC injection (research vials) |
| Typical dose range | 1–2 capsules twice daily for 30 days (label); 1–3 mg daily for 10–30 days (community protocols) |
| Evidence level | Limited: cell and rodent studies plus one small uncontrolled human study, all from the developer network |
| Regulatory status | Capsules sold as food supplements; not an approved medicine (FDA, EMA); not named by WADA, falls under S0 |
How it works
In rat cerebellar neurons, neutrophils and PC12 cells, Pinealon limited the build-up of reactive oxygen species in a dose-dependent way and reduced necrotic cell death, with delayed ERK1/2 activation and cell-cycle changes [1]. Fluorescently labelled Pinealon entered the cytoplasm, nucleus and nucleolus of HeLa cells [2], and spectroscopy and molecular dynamics suggest it can sit partly in the major groove of DNA [3]. In aging brain-cortex cultures, EDR increased serotonin expression, and docking placed it on a sequence in the tryptophan hydroxylase gene [4].
These results describe a plausible antioxidant and gene-regulatory story in cells. They do not show what an oral capsule does in a human brain.
What the evidence shows
Human studies
| Study | Design | n | Finding | Certainty |
|---|---|---|---|---|
| Meshchaninov et al. 2015 [5] | Russian study in adults aged 41–83 with polymorbidity and organic brain syndrome; Pinealon or Vesugen | 32 | Reported “anabolic” effects and slower biological-age indicators; Vesugen did better than Pinealon; also a pro-oxidant signal and lower CD34+ cells | Very low: control group and randomisation not described in the abstract, small, single centre |
A Russian review summarises clinical use of short neuroprotective peptides including Pinealon in older people, without trial data I could verify [6].
Animal and cell studies
| Study | Model | Finding |
|---|---|---|
| Khavinson et al. 2021 [7] | 5xFAD Alzheimer mice | EDR and KED prevented dendritic spine loss |
| Khavinson et al. 2020 [8] | Review of neuronal culture work | Reduced dendritic spine elimination in Alzheimer and Huntington models |
| Arutjunyan et al. 2012 [9] | Offspring of pregnant rats with high homocysteine | Better learning and less neuronal oxidative stress when mothers received Pinealon |
| Mendzheritsky et al. 2015 [10] | 18-month-old rats under hypoxia or cold stress | Changes in brain monoamines; Cortexin had stronger antioxidant effects than Pinealon |
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Standard Cytogen course | 1–2 capsules | Oral, with meals | Twice daily | 30 days, repeat after 3–6 months | Label (ipept.eu; NPCRIZ Europe Cytogen directions) |
| Brain fog / stress course | 1–3 mg | Oral, usually in the morning | Once daily | 20–30 days, then about 3 months off | Practice protocol (practitioner protocols quoted by Alexander Cortes; 1 mg oral courses also described there) |
| Injectable course | 1–2 mg | SC injection | Once daily | 10–20 days, 1–3 courses a year | Practice protocol (r/peptidebioregulators; 2 mg alongside Vesugen on PeptideCritic) |
| Pineal-brain stack | Pinealon + Epithalon | Oral or SC | Pinealon morning, Epithalon evening | 20–30 days, twice a year | Practice protocol (Alexander Cortes; stacking also on r/Nootropics) |
| Vascular-brain stack | Pinealon 2 mg + Vesugen 1 mg | SC injection | Once daily | Course length not stated | Anecdotal (PeptideCritic) |
Epithalon dosing is covered in the Epithalon dosage guide. Injection technique: peptide injection guide.
What people report: what works and what doesn’t
Reported to work
- The most common report is less brain fog and clearer mornings within about 10 days at roughly 1 mg orally, especially under stress (Alexander Cortes, citing practitioner and user posts).
- A widely linked 2018 self-experiment described injecting Pinealon extracted from capsules and reported strong cognitive effects (r/Nootropics thread summary). That is a single uncontrolled experiment.
Mixed or unclear
- Sleep effects are inconsistent: some people sleep better, others find it activating; practitioners describe these effects as transient and dependent on baseline stress (Alexander Cortes).
- Overall community experience ranges from “waste of time” to “profound benefits” (r/Nootropics).
Reported not to work / disappointing
- Users of capsule bioregulators often report no noticeable change, and doubt about oral absorption is common (r/Biohackers).
A trial worth believing would randomise older adults with subjective cognitive decline to Pinealon or placebo and measure validated cognitive tests and sleep objectively.
Safety and side effects
- No adequate human safety data. The one human study noted a pro-oxidant signal and lower circulating CD34+ cells [5], unexplained and not followed up.
- Cognitive symptoms need a work-up first: thyroid, B12, sleep apnoea, depression, medications, vascular risk.
- Product quality: Pinealon is hygroscopic and slow to dry during synthesis, so vial content may be off (Longecity).
- Pregnancy, active cancer: no data; avoid.
Legal and regulatory status
- US: not FDA-approved; imported capsules and “research use only” vials are not approved for human use.
- EU / Germany: not authorised as a medicine by the EMA or BfArM.
- Sport: not named on the WADA 2026 list; falls under S0.
How it fits
Pinealon sits between Epithalon (pineal, telomeres, melatonin) and Cortagen (cortex, nerve repair). Semax and Selank have small Russian clinical trials and are the better-studied options for cognition and stress. Vesugen shares the only human study.
Related Articles
- Peptide Bioregulators: The Khavinson Protocol and What the Evidence Shows
- Epithalon Dosage and Cycling Protocols
- Semax: The Nootropic Peptide That Amplifies BDNF
- DSIP: Delta Sleep-Inducing Peptide for Sleep
- Brain Fog Overview
Frequently asked questions
What is Pinealon?
Pinealon is the synthetic tripeptide Glu-Asp-Arg (EDR) from the Khavinson bioregulator programme, sold as Cytogen capsules and injectable vials for brain function and neuroprotection.
Is Pinealon a sleep peptide?
It is marketed for brain function rather than sleep. Some users report better sleep, others report the opposite; there are no human sleep studies.
What is the difference between Pinealon and Epithalon?
Epithalon (Ala-Glu-Asp-Gly) is the pineal tetrapeptide studied for telomerase and melatonin. Pinealon (Glu-Asp-Arg) is a brain-focused tripeptide studied for oxidative stress and neuron survival. People often stack them.
What dose of Pinealon do people use?
Capsule directions are 1–2 capsules twice daily with meals for 30 days. Community protocols report 1–3 mg a day orally for 10–30 days, or 1–2 mg SC daily for 10–20 days. None comes from a dose-finding trial.
Does Pinealon help Alzheimer's disease?
It prevented dendritic spine loss in cell and mouse models of Alzheimer's disease. No human Alzheimer's trial exists.
References
- Khavinson V, Ribakova Y, Kulebiakin K, et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res. 2011. https://pubmed.ncbi.nlm.nih.gov/21978084/
- Fedoreyeva LI, Kireev II, Khavinson VKh, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011. https://pubmed.ncbi.nlm.nih.gov/22117547/
- Silanteva IA, Komolkin AV, Morozova EA, et al. Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction. J Phys Chem B. 2019. https://pubmed.ncbi.nlm.nih.gov/30762356/
- Khavinson VKh, Lin’kova NS, Tarnovskaya SI, et al. Short peptides stimulate serotonin expression in cells of brain cortex. Bull Exp Biol Med. 2014. https://pubmed.ncbi.nlm.nih.gov/24909721/
- Meshchaninov VN, Tkachenko EL, Zharkov SV, et al. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission (in Russian). Adv Gerontol. 2015. https://pubmed.ncbi.nlm.nih.gov/26390612/
- Umnov RS, Lin’kova NS, Khavinson VKh. Neuroprotective effects of peptides bioregulators in people of various age (in Russian). Adv Gerontol. 2013. https://pubmed.ncbi.nlm.nih.gov/24738258/
- Khavinson V, Ilina A, Kraskovskaya N, et al. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer’s Disease. Pharmaceuticals (Basel). 2021. https://pubmed.ncbi.nlm.nih.gov/34071923/
- Khavinson V, Linkova N, Kozhevnikova E, et al. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease. Molecules. 2020. https://pubmed.ncbi.nlm.nih.gov/33396470/
- Arutjunyan A, Kozina L, Stvolinskiy S, et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med. 2012. https://pubmed.ncbi.nlm.nih.gov/22567179/
- Mendzheritsky AM, Karantysh GV, Ryzhak GA, et al. Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia (in Russian). Adv Gerontol. 2015. https://pubmed.ncbi.nlm.nih.gov/28509493/
Disclaimer: This article is for informational and educational purposes only and is not a prescription or individual medical advice. Pinealon is not approved by the FDA or the EMA.
